Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Long-Term Outcomes of Homografts in the Aortic Valve and Root Position: A 20-Year Experience

  • Kim, Joo Yeon (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Joon Bum (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jung, Sung-Ho (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choo, Suk Jung (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Chung, Cheol Hyun (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jae Won (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2015.08.31
  • Accepted : 2015.10.20
  • Published : 2016.08.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The advantages of using a homograft in valve replacement surgery are the excellent hemodynamic profile, low risk of thromboembolism, and low risk of prosthetic valve infection. The aim of this study was to evaluate the long-term outcomes of homograft implantation in the aortic valve position. Methods: This is a retrospective study of 33 patients (>20 years old) who underwent aortic valve replacement or root replacement with homografts between April 1995 and May 2015. Valves were collected within 24 hours from explanted hearts of heart transplant recipients (<60 years) and organ donors who were not suitable for heart transplantation. The median follow-up duration was 35.6 months (range, 0 to 168 months). Results: Aortic homografts were used in all patients. The 30-day mortality rate was 9.1%. The 1- and 5-year survival rates were $80.0%{\pm}7.3%$ and $60.8%{\pm}10.1%$, respectively. The 1-, 5-, and 10-year freedom from reoperation rates were $92.3%{\pm}5.2%$, $68.9%{\pm}10.2%$, and $50.3%{\pm}13.6%$, respectively. The 1-, 5-, and 10-year freedom from significant aortic dysfunction rates were $91.7%{\pm}8.0%$, $41.7%{\pm}14.2%$, and $25.0%{\pm}12.5%$, respectively. Conclusion: Homografts had the advantages of a good hemodynamic profile and low risk of thromboembolic events, and with good outcomes in cases of aortitis.

Keywords

References

  1. O'Brien MF, Harrocks S, Stafford EG, et al. The homograft aortic valve: a 29-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Dis 2001;10:334-44.
  2. Staab ME, Nishimura RA, Dearani JA, Orszulak TA. Aortic valve homografts in adults: a clinical perspective. Mayo Clin Proc 1998;73:231-8. https://doi.org/10.4065/73.3.231
  3. Kim JH, Na CY, Oh SS, Lee CH, Baek MJ, Kim CW. Homograft aortic root replacement. Korean J Thorac Cardiovasc Surg 2005;38:197-203.
  4. Park S, Hwang HY, Kim KH, Kim KB, Ahn H. Midterm follow-up after cryopreserved homograft replacement in the aortic position. Korean J Thorac Cardiovasc Surg 2012;45: 30-4. https://doi.org/10.5090/kjtcs.2012.45.1.30
  5. Preventza O, Mohamed AS, Cooley DA, et al. Homograft use in reoperative aortic root and proximal aortic surgery for endocarditis: a 12-year experience in high-risk patients. J Thorac Cardiovasc Surg 2014;148:989-94. https://doi.org/10.1016/j.jtcvs.2014.06.025
  6. Fukushima S, Tesar PJ, Pearse B, et al. Long-term clinical outcomes after aortic valve replacement using cryopreserved aortic allograft. J Thorac Cardiovasc Surg 2014;148:65-72.e2. https://doi.org/10.1016/j.jtcvs.2013.07.038
  7. Koolbergen DR, Hazekamp MG, de Heer E, et al. The pathology of fresh and cryopreserved homograft heart valves: an analysis of forty explanted homograft valves. J Thorac Cardiovasc Surg 2002;124:689-97. https://doi.org/10.1067/mtc.2002.124514
  8. Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B. Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation 2010;121:2123-9. https://doi.org/10.1161/CIRCULATIONAHA.109.901272
  9. Nguyen DT, Delahaye F, Obadia JF, et al. Aortic valve replacement for active infective endocarditis: 5-year survival comparison of bioprostheses, homografts and mechanical prostheses. Eur J Cardiothorac Surg 2010;37:1025-32. https://doi.org/10.1016/j.ejcts.2009.11.035
  10. Yankah AC, Klose H, Petzina R, Musci M, Siniawski H, Hetzer R. Surgical management of acute aortic root endocarditis with viable homograft: 13-year experience. Eur J Cardiothorac Surg 2002;21:260-7. https://doi.org/10.1016/S1010-7940(01)01084-3
  11. Jeong DS, Kim KH, Kim JS, Ahn H. Long-term experience of surgical treatment for aortic regurgitation attributable to Behcet's disease. Ann Thorac Surg 2009;87:1775-82. https://doi.org/10.1016/j.athoracsur.2009.03.008
  12. Ma WG, Zheng J, Zhu JM, Liu YM, Li M, Sun LZ. Aortic regurgitation caused by Behcet's disease: surgical experience during an 11-year period. J Card Surg 2012;27:39-44. https://doi.org/10.1111/j.1540-8191.2011.01392.x

Cited by

  1. An Aortic Root Abscess Presenting as a Suprasternal Pulsatile Mass vol.52, pp.3, 2016, https://doi.org/10.5090/kjtcs.2019.52.3.178
  2. Recent Advancements in 3D Printing and Bioprinting Methods for Cardiovascular Tissue Engineering vol.8, pp.10, 2021, https://doi.org/10.3390/bioengineering8100133